Physician profile
Peter Gobar
NPI 1164408761
$3,486.76
in general payments reported to CMS, 2019-2025
20 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $280 · 2023: $788 · 2024: $1,274 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $572.48 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $517.39 | 2022-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $438.77 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $276.26 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $276.16 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $214.88 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Livanova USA, INC. | $171.41 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Axsome Therapeutics, INC. | $146.72 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $136.47 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.84 | 2024-2025 | Caplyta |
| Alkermes, INC. | $127.65 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $101.75 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $78.35 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $76.10 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $69.14 | 2023-2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $57.01 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $41.29 | 2024-2025 | Qelbree |
| Noven Therapeutics, LLC | $21.23 | 2024 | Secuado, Xelstrym |
| Tempus Ai, INC | $18.96 | 2024 | |
| Collegium Pharmaceutical, INC. | $14.90 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.